Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 224-314-4 | CAS number: 4303-67-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 03 September 1986 to 17 October 1986
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study was performed prior to OECD guidelines and was not GLP compliant. Test method was an acute oral toxicity test in 5 rats/sex/group that received 400, 500, 640 or 1000 mg/kg test material as a single oral gavage. Sufficient information was available for hazard classification per Annex VI of the CLP criteria.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: ANSI/ADA Doc No. 41A (1982)
- Deviations:
- no
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Lauryl imidazole
- IUPAC Name:
- Lauryl imidazole
- Details on test material:
- - Name of test material (as cited in study report): Lauryl imidazole
- Substance type: Pure active substance
- Physical state: Liquid
- Analytical purity: 99%
- Purity test date: 22 July 1986
- Lot/batch No.: Batch 0001
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Interfauna UK Ltd., Huntingdon, Cambridgeshire, England
- Age at study initiation: 4-6 weeks
- Weight at study initiation: 200-266g
- Fasting period before study: 4 hours prior to dosing
- Housing: IN groups by sex in metal cages with wire mesh floors
- Diet (e.g. ad libitum): Standard laboratory rodent diet (Labsure LAD1) ad libitum
- Water (e.g. ad libitum): Tap water ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-24
- Humidity (%): Mean: 66
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 03 September 1986 To: 17 October 1986
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 1.12 mL/kg
- Doses:
- 400, 500, 640, or 1000 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: 0.5, 1, 2, 3, 4, 5, and 6 hours after dosing (Day 1) and then at least once daily through Day 15
- Necropsy of survivors performed: macroscopic necropsy performed on all animals
- Other examinations performed: clinical signs, body weight
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 641 mg/kg bw
- Based on:
- act. ingr.
- 95% CL:
- >= 558 - <= 759
- Mortality:
- Animal(s) died in the 500 mg/kg (1/5 females), 640 mg/kg (2/5 males and 5/5 females), and 1000 mg/kg (4/5 males, 5/5 females) treated groups from Day 2 to Day 5.
- Clinical signs:
- other: Piloerection and increased salivation were observed in all rats. Hunched posture was observed in all animals except one male and one female of the 1000 mg/kg group. Clinical signs with dose dependent increases in incidence included: decreased respiratory
- Gross pathology:
- No gross abnormalities were observed upon macroscopic necropsy.
Applicant's summary and conclusion
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Based on the results of this study (10% mortality at 500 mg/kg and increasing mortality at 1000 mg/kg), the rat oral LD50 is 641 mg/kg with 95% confidence limits of 558 to 759 mg/kg.
- Executive summary:
The acute oral toxicity potential of the test article (yellow liquid, purity 99% CASRN 4303-67-7, batch 0001) was tested in male and female CFY Sprague Dawley rats. The experimental procedure was based on ANSI/ADA Document number 41a 1982. The test article was administered as received via oral gavage. Rats (5/sex/group) received 400, 500, 640, or 1000 mg/kg test article. Clinical observations were recorded at 0.5, 1, 2, 3, 4, 5, and 6 hours after dosing (Day 1) and then at least once daily through Day 15. Body weights were recorded on Day 1, 8, 15 and on the day of death. Surviving animals on Day 15 were euthanatized and received macroscopic necropsy examination. Animal(s) died in the 500 mg/kg (1/5 females), 640 mg/kg (2/5 males and 5/5 females), and 1000 mg/kg (4/5 males, 5/5 females) treated groups from Day 2 to Day 5. Animals that survived to Day 6 survived until the end of the study on Day 15. Animals that died prematurely had congestion of the stomach and pallor of the liver, kidneys, and/or spleen. Body weight losses were recorded for all rats found dead. Piloerection and increased salivation were observed in all rats. Hunched posture was observed in all animals except one male and one female of the 1000 mg/kg group. Clinical signs with dose dependent increases in incidence included: decreased respiratory rate, ptosis, pallor of the extremities, diarrhea, increased lachrymation, and prostration. Lethargy and abnormal gait (waddling) were observed in 3-5 animals/sex in the 400, 640, and 1000 mg/kg dose groups and only 1 female in the 500 mg/kg group. Body weight losses or decreased gains were recorded among surviving male rats of all groups on Day 4 and among surviving female rats on Days 4 and 8. All surviving rats achieved anticipated body weight gains during the second week of the study with the exclusion of one female rat that had slightly decreased gain on Day 15. Terminal necropsies were normal. The oral LD50 with a 95% confidence interval was calculated using probit analysis by a log transformation of the dose relative to percent mortality. Based on the results of this study (10% mortality at 500 mg/kg and increasing up to 90% mortality at 1000 mg/kg), the rat oral LD50 is 641 mg/kg with 95% confidence limits of 558 to 759 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.